Summary of Key Points Core Viewpoint - On November 25, a block trade of 1.59 million shares of Ruizhi Pharmaceutical was executed at a transaction price of 8.23 yuan, representing a discount of 20.48% compared to the market closing price of 10.35 yuan, with a total transaction value of 13.0857 million yuan, accounting for 16.79% of the total trading volume for the day [1]. Group 1: Transaction Details - The block trade involved 1.59 million shares of Ruizhi Pharmaceutical, with a transaction price of 8.23 yuan per share [2]. - The total transaction amount reached 13.0857 million yuan, which is approximately 1.30857 million [2]. - The trade accounted for 16.79% of the total trading volume on that day [1]. Group 2: Market Context - The transaction price of 8.23 yuan reflects a significant discount of 20.48% from the market closing price of 10.35 yuan [1]. - The buyer was from CITIC Securities, while the seller was from Huafu Securities [2].

Core Viewpoint - The company, Ruizhi Pharmaceutical, announced a strategic partnership with professional investment institutions to enhance its capabilities in the innovative drug industry through a new investment fund [2] Group 1: Investment Details - The company’s wholly-owned subsidiary, Beihai Ruizhi Venture Capital Co., Ltd., will collaborate with Shenzhen Investment Control Donghai Investment Co., Ltd. and other partners to establish a new investment fund named Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Partnership [2] - The total committed capital for the partnership is set at RMB 200 million, with Beihai Ruizhi contributing RMB 58 million, representing 29% of the total [2] - The partnership has completed the necessary registration and obtained the Private Investment Fund Registration Certificate in compliance with relevant Chinese regulations [2]

Core Insights - The world's first drug manufacturing system suitable for ADC (Antibody-Drug Conjugates) and nucleotide monomer synthesis was officially launched in Shanghai [1] - This system, developed by Ruizhi Pharmaceutical in collaboration with East China Normal University, utilizes femtosecond laser technology to carve complex chemical factories on chips [1] - The system is expected to usher the pharmaceutical industry into a new era of continuous, miniaturized, and intelligent manufacturing [1] Cost and Efficiency - The new system significantly shortens the drug development cycle and reduces the cost of nucleotide monomer synthesis by over 40% [1] - It addresses issues related to expensive raw materials and long reaction times inherent in traditional processes [1] Future Implications - The future of drug production is anticipated to shift towards "on-demand intelligent manufacturing," moving away from reliance on centralized large factories [1] - Production may become decentralized, extending to hospitals, communities, and even households [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、与专业机构共同投资的概述 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 9 月 3 日召开 第六届董事会第十一次会议，审议通过了《关于全资子公司与专业投资机构共同 投资的议案》。为借助专业投资机构的投资能力、资金优势及风险控制能力，赋 能创新药产业协同，公司全资子公司北海睿智创业投资有限公司（以下简称"北 海睿智"）与专业投资机构深圳市投控东海投资有限公司（以下简称"投控东海"、 "基金管理人"）及其他有限合伙人深圳市罗湖产业促进合伙企业（有限合伙） 拟共同出资设立深圳市罗湖东海睿智医药产业合伙企业（有限合伙）（以下简称 "合伙企业"或"基金"），全体合伙人认缴出资总额为人民币 20,000 万元， 其中北海睿智作为有限合伙人以自有资金出资人民币 5,800 万元，占认缴出资总 额 的 29% 。 具 体 内 容 详 见 公 司 于 2025 年 9 月 3 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）上披露的《关于全资子公司与专业投资机构共同投资的公 告》（公告编号：2 ...

Core Insights - The recent launch of the drug micro-manufacturing system by Ruizhi Pharmaceutical in collaboration with East China Normal University marks a significant advancement in the field of antibody-drug conjugates (ADCs) and nucleotide phosphoramidite monomer synthesis [1][2] - This intelligent micro-flow technology addresses the bottleneck of "pilot scale-up" in drug development, transforming traditional production methods into continuous, smart, and precise "desktop" manufacturing [1] - The ADC micro-manufacturing system integrates multiple steps of the coupling reaction into a single chip, allowing for millisecond-level monitoring and precise control of key quality attributes, significantly reducing batch-to-batch variability [1] Summary by Sections Technology and Innovation - The newly released ADC micro-manufacturing system can shorten the process development and optimization time from weeks to days [1] - Key technical challenges such as chip manufacturing, stability, and multiphase fluid control have been overcome, achieving a 100% localization rate for core components and reducing overall costs by over 50% compared to imported solutions [1] Company Strategy and Market Position - The drug micro-manufacturing system enhances the company's one-stop, platform-based service capability, marking a significant step towards achieving certainty in ADC and small nucleic acid drug development [2] - The system is expected to reduce ADC drug process development time by 70% and lower the cost of nucleotide monomer synthesis by over 40% [2] - Ruizhi Pharmaceutical currently provides comprehensive new drug lifecycle services to global pharmaceutical companies, biotech firms, and research institutions, having established strategic partnerships with over 150 leading biopharmaceutical research organizations and enterprises [2] Educational Collaboration - East China Normal University's School of Pharmacy, established in May 2023, focuses on developing cutting-edge technologies such as artificial intelligence pharmacy, drug manufacturing, digital drugs, and nucleic acid and cell drugs [2] - The school aims to become a leading base for drug science and a training ground for future pharmaceutical talent, addressing both international frontiers and national strategic needs [2]

Core Insights - The release of the world's first intelligent manufacturing system for ADC (Antibody-Drug Conjugates) and nucleotide monomer drugs was announced by Ruizhi Pharmaceutical in collaboration with East China Normal University [1] - This innovative achievement is expected to drive the pharmaceutical industry towards continuous, miniaturized, and intelligent upgrades, reshaping the overall paradigm of drug research and production [1] - The development signifies China's achievement in achieving self-control in core biopharmaceutical process equipment, providing new momentum for the high-quality development of China's innovative drug industry [1]

Core Insights - Ruizhi Pharmaceutical reported that as of November 10, 2025, the number of shareholders is 40,581 [2] Company Summary - The company has engaged with investors through an interactive platform, providing updates on shareholder numbers [2]

本所律师根据《中华人民共和国公司法》（以下简称《公司法》）、《中华 人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》（以下 简称《股东会规则》）、《律师事务所从事证券法律业务管理办法》（以下简称 《证券法律业务管理办法》）、《律师事务所证券法律业务执业规则（试行）》 （以下简称《证券法律业务执业规则》）等相关法律、行政法规、规章、规范性 文件及《睿智医药科技股份有限公司章程》（以下简称《公司章程》）的规定， 就本次会议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序 及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅就本次会议的召集与召开程序、召集人和出席现场会议人员 资格、会议表决程序及表决结果的合法性发表意见，不对本次会议所审议的议案 内容及该等议案所表述的事实或数据的真实性、准确性和完整性发表意见； 上海市徐汇区淮海中路 1010 号嘉华中心 45 层 邮编：200031 电话：(86-21) 5404 9930 传真：(86-21) 5404 9931 北京市竞天公诚律师事务所上海分所 关于睿智医药科技股份有限公司 2025 ...

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形。 证券代码：300149 证券简称：睿智医药 公告编号：2025-76 睿智医药科技股份有限公司 2025 年第二次临时股东会决议公告 2、本次股东会无变更提案的情况。 一、会议召开和出席情况 1、召开方式：本次会议采取现场投票与网络投票相结合的方式。 2、现场会议地点：上海市浦东新区张江高科技园区金科路 2829 号金科中心 A 栋 3、现场会议召开时间：2025 年 11 月 17 日下午 14:30 4、网络投票时间：2025 年 11 月 17 日。其中，通过深圳证券交易系统进行网络 投票的具体时间为 2025 年 11 月 17 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网投票的具体时间为 2025 年 11 月 17 日上午 9:15 至下午 15:00 期间的任意时间。 5、召集人：公司董事会 6、出席现场会议和参加网络投票的股东及股东代表共 264 人，所持（代理）有 表决权的股份总数 172, ...

Core Insights - The company is collaborating with professional investment institutions to establish an investment fund through a CVC model, focusing on innovative drug projects [1] - The company aims to achieve a revenue growth rate of no less than 15% by 2025 and to turn net profit positive (excluding equity incentive expenses) [1] Group 1 - The company’s wholly-owned subsidiary is involved in the investment fund initiative [1] - The investment strategy is designed to empower industrial collaboration and expand future orders [1] - The company is advancing its operational efforts around equity incentive goals [1]